Clinical Trial Update: Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream [Phase 3]

View source ↗

Summary

Phase 3 open-label trial evaluating whether imiquimod 5% cream clears superficial basal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Superficial Basal Cell Carcinoma

Drugs mentioned

• Imiquimod 5% cream (Imiquimod)

Snippet

Sponsor: Graceway Pharmaceuticals, LLC | Conditions: Superficial Basal Cell Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2008-11-26